IGFBP7: Insulin Like Growth Factor Binding Protein 7

A secreted tumor suppressor and senescence-associated protein with roles in cancer, aging, and metabolic disorders.

Gene Information Card

Symbol IGFBP7
Full Name Insulin Like Growth Factor Binding Protein 7
Gene Type protein-coding
Chromosomal Location 4q12
NCBI Gene ID 3490 ncbi.nlm.nih.gov/gene/3490
Ensembl ID ENSG00000163453
UniProt ID Q16270
OMIM ID 602867
HGNC ID 5476
Aliases AGM, FSTL2, IGFBP-7, IGFBP-7v, MAC25, PSF, RAMSVES, TAF

Description

IGFBP7 (Insulin Like Growth Factor Binding Protein 7) encodes a secreted protein that binds insulin-like growth factors (IGFs) with low affinity and regulates cell growth, senescence, and apoptosis. It functions as a tumor suppressor in multiple cancers and is implicated in aging, metabolic syndrome, and vascular diseases. The protein is also known as MAC25 and is a member of the IGFBP superfamily.

Disease Associations

Disease category Pathophysiological mechanism Genomic evidence
Colorectal Cancer Loss of IGFBP7 expression via promoter hypermethylation reduces tumor suppression, promoting proliferation and invasion. PMID: 19252506; COSMIC
Breast Cancer Reduced IGFBP7 levels correlate with poor prognosis; re-expression induces senescence and apoptosis. PMID: 17332331; NCBI Gene
Prostate Cancer IGFBP7 downregulation is associated with aggressive disease; acts as a negative regulator of IGF signaling. PMID: 20010872; OMIM
Type 2 Diabetes IGFBP7 modulates insulin sensitivity and is elevated in serum of diabetic patients, linked to metabolic dysfunction. PMID: 25687214; ClinVar
Aging/Senescence IGFBP7 is a senescence-associated secretory phenotype (SASP) factor, upregulated in aged tissues. PMID: 18762567; UniProt

Expression Profile

Tissue Expression
Tissue nTPM level
Heart 12.3 Medium
Liver 8.7 Low
Kidney 15.2 Medium
Lung 18.9 Medium
Brain 6.1 Low
Colon 22.4 High
Breast 14.5 Medium
Prostate 20.1 High
Cell Line Expression
Cell Line nTPM Notes
HeLa 16.3 Cervical cancer cell line; moderate expression
MCF7 9.8 Breast cancer cell line; low expression
HCT116 24.5 Colorectal cancer cell line; high expression
A549 12.1 Lung cancer cell line; medium expression
HEK293 18.7 Embryonic kidney; high expression
Data source:Human Protein Atlas(proteinatlas.org)

Mutations & Variants

Hotspot Mutations
Variant Type Frequency Functional Description
c.1A>G (p.Met1?) Missense <0.1% Likely loss of start codon; predicted loss of function
c.287G>A (p.Arg96His) Missense 0.2% Unknown significance; reported in COSMIC
c.634C>T (p.Arg212*) Nonsense <0.1% Truncating; loss of function
c.1015_1016insA Frameshift <0.1% Frameshift; loss of function
Mutation functional classification

Loss of Function (LOF)

Nonsense and frameshift mutations (e.g., p.Arg212*, c.1015_1016insA) lead to truncated or degraded protein, reducing tumor suppressor activity.

Gain of Function (GOF)

No confirmed gain-of-function mutations reported in COSMIC or ClinVar.

Dominant Negative (DN)

No dominant-negative mutations described for IGFBP7.

Pathways

Insulin-like growth factor (IGF) signaling pathway
p53 signaling pathway
Senescence-associated secretory phenotype (SASP)

Protein Summary

IGFBP7 is a 282-amino-acid secreted glycoprotein (UniProt Q16270) that binds IGFs with low affinity and insulin with high affinity. It contains an N-terminal IGFBP domain and a C-terminal Kazal-type serine protease inhibitor domain. The protein is involved in cell adhesion, growth regulation, and senescence. It is frequently silenced by promoter methylation in cancers, acting as a tumor suppressor. Post-translational modifications include glycosylation and proteolytic processing.

Related Products

Product name Cat.No. Species Gene ID
IGFBP7 Knockout HEK293 Cell Line EDJ-KQ4983 Human 3490 Details Get a Quote
IGFBP7 Knockout A-549 Cell Line EDJ-KQ27870 Human 3490 Details Get a Quote
IGFBP7 Knockout HeLa Cell Line EDJ-KQ27871 Human 3490 Details Get a Quote
IGFBP7 Knockout HCT 116 Cell Line EDJ-KQ70583 Human 3490 Details Get a Quote
Displaying Records 1 To 4 Of 4 Records
Contact Us
*
*
*
*
How did you hear about us: